Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12


Optimizing colorectal cancer screening by race and sex: Microsimulation analysis II to inform the American Cancer Society colorectal cancer screening guideline.

Meester RGS, Peterse EFP, Knudsen AB, de Weerdt AC, Chen JC, Lietz AP, Dwyer A, Ahnen DJ, Siegel RL, Smith RA, Zauber AG, Lansdorp-Vogelaar I.

Cancer. 2018 Jul 15;124(14):2974-2985. doi: 10.1002/cncr.31542. Epub 2018 May 30.


The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: Microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline.

Peterse EFP, Meester RGS, Siegel RL, Chen JC, Dwyer A, Ahnen DJ, Smith RA, Zauber AG, Lansdorp-Vogelaar I.

Cancer. 2018 Jul 15;124(14):2964-2973. doi: 10.1002/cncr.31543. Epub 2018 May 30.


Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.

Peterse EFP, Niessen B, Addie RD, de Jong Y, Cleven AHG, Kruisselbrink AB, van den Akker BEWM, Molenaar RJ, Cleton-Jansen AM, Bovée JVMG.

Br J Cancer. 2018 Apr;118(8):1074-1083. doi: 10.1038/s41416-018-0050-9. Epub 2018 Mar 26.


Value Of Waiving Coinsurance For Colorectal Cancer Screening In Medicare Beneficiaries.

Peterse EFP, Meester RGS, Gini A, Doubeni CA, Anderson DS, Berger FG, Zauber AG, Lansdorp-Vogelaar I.

Health Aff (Millwood). 2017 Dec;36(12):2151-2159. doi: 10.1377/hlthaff.2017.0228.


NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma.

Peterse EFP, van den Akker BEWM, Niessen B, Oosting J, Suijker J, de Jong Y, Danen EHJ, Cleton-Jansen AM, Bovée JVMG.

Mol Cancer Res. 2017 Dec;15(12):1714-1721. doi: 10.1158/1541-7786.MCR-17-0293. Epub 2017 Aug 31.


A researcher's perspective on the quantity of osteosarcoma in vitro studies.

Peterse EFP, van Leeuwen TN, Cleton-Jansen AM.

J Bone Oncol. 2017 Apr 7;7:29-31. doi: 10.1016/j.jbo.2017.04.004. eCollection 2017 Jun.


No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone.

Peterse EF, Cleven AH, De Jong Y, Briaire-de Bruijn I, Fletcher JA, Danen EH, Cleton-Jansen AM, Bovée JV.

BMC Cancer. 2016 Jul 14;16:475. doi: 10.1186/s12885-016-2522-8.


Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway.

van Maldegem AM, Bovée JV, Peterse EF, Hogendoorn PC, Gelderblom H.

Eur J Cancer. 2016 Jan;53:171-80. doi: 10.1016/j.ejca.2015.09.009. Epub 2016 Jan 5. Review.


CORR Insights(®): Transcriptional Profiling Identifies the Signaling Axes of IGF and Transforming Growth Factor-β as Involved in the Pathogenesis of Osteosarcoma.

Peterse EF, Bovée JV.

Clin Orthop Relat Res. 2016 Jan;474(1):190-2. doi: 10.1007/s11999-015-4620-3. Epub 2015 Nov 12. No abstract available.


Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin.

Baranski Z, de Jong Y, Ilkova T, Peterse EF, Cleton-Jansen AM, van de Water B, Hogendoorn PC, Bovée JV, Danen EH.

Oncotarget. 2015 Nov 3;6(34):36113-25. doi: 10.18632/oncotarget.5333.


A polymorphic p53 response element in KIT ligand influences cancer risk and has undergone natural selection.

Zeron-Medina J, Wang X, Repapi E, Campbell MR, Su D, Castro-Giner F, Davies B, Peterse EF, Sacilotto N, Walker GJ, Terzian T, Tomlinson IP, Box NF, Meinshausen N, De Val S, Bell DA, Bond GL.

Cell. 2013 Oct 10;155(2):410-22. doi: 10.1016/j.cell.2013.09.017.


IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma.

Kuijjer ML, Peterse EF, van den Akker BE, Briaire-de Bruijn IH, Serra M, Meza-Zepeda LA, Myklebost O, Hassan AB, Hogendoorn PC, Cleton-Jansen AM.

BMC Cancer. 2013 May 20;13:245. doi: 10.1186/1471-2407-13-245.

Supplemental Content

Loading ...
Support Center